BioCryst Pharmaceuticals (US.BCRX)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.BCRX · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.7% | → |
| ROE | - | → |
| Cash Conversion | - | → |
| D/E Ratio | - | → |
| Gross Margin | 96.6% | → |
US.BCRX (BioCryst Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.7% → ROE - → Cash Conversion - → D/E Ratio - → Gross Margin 96.6% →
Key Metrics
US.BCRX (BioCryst Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.7% →ROE - →Cash Conversion - →D/E Ratio - →Gross Margin 96.6% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies